

Helen Gogas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2610500/publications.pdf>

Version: 2024-02-01

127
papers

13,094
citations

172457

29
h-index

24258

110
g-index

129
all docs

129
docs citations

129
times ranked

17007
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600 mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	1.6	90
2	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. <i>European Journal of Cancer</i> , 2022, 163, 79-87.	2.8	17
3	Multichamber Involvement of Metastatic Cardiac Melanoma. <i>Diagnostics</i> , 2022, 12, 587.	2.6	3
4	Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047). <i>Journal of Clinical Oncology</i> , 2022, 40, 360385-360385.	1.6	33
5	Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103663.	4.4	27
6	Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. <i>British Journal of Cancer</i> , 2022, 127, 695-703.	6.4	2
7	Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9535-9535.	1.6	8
8	Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor. <i>Cancer Research</i> , 2022, 82, CT557-CT557.	0.9	2
9	Dabrafenib (D) and trametinib (T) plus spaltalizumab (S) in patients (pts) with previously untreated <i>BRAF</i> V600 mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9527-9527.	1.6	2
10	Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti-PD-1 therapy: MASTERKEY-115.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9518-9518.	1.6	4
11	Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in <i>BRAF</i> V600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9547-9547.	1.6	5
12	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced <i>BRAF</i> V600-positive melanoma: Interim analysis of the ImmunoCobiVem study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9548-9548.	1.6	6
13	EMRseq: Registry-based outcome analysis on 1,000 patients with <i>BRAF</i> V600 mutated metastatic melanoma in Europe treated with either immune checkpoint or <i>BRAF</i> /MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9540-9540.	1.6	5
14	Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers. <i>Cancers</i> , 2022, 14, 2873.	3.7	1
15	Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9505-9505.	1.6	8
16	Androgen Receptor and <i>PIM1</i> Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 147-156.	2.0	4
17	Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci <i>et al</i> ., 2021, 9, e002391.		3
18	Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. , 2021, 9, e001621.		32

#	ARTICLE	IF	CITATIONS
19	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 301-314.	6.7	18
20	Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors. <i>Cancer Immunology Research</i> , 2021, 9, 726-734.	3.4	19
21	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers</i> , 2021, 13, 2466.	3.7	7
22	Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review. <i>BMC Gastroenterology</i> , 2021, 21, 227.	2.0	7
23	Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	4.2	16
24	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021, 152, 116-128.	2.8	7
25	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
26	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. <i>Vaccines</i> , 2021, 9, 1017.	4.4	10
27	Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 349-360.	0.7	0
28	Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. <i>Vaccines</i> , 2021, 9, 1111.	4.4	22
29	Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 727010.	2.8	2
30	The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 17588359211047349.	3.2	0
31	Application of the International System for Reporting Serous Fluid Cytopathology with Cytohistological Correlation and Risk of Malignancy Assessment. <i>Diagnostics</i> , 2021, 11, 2223.	2.6	11
32	The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110473.	3.2	9
33	The Role of CXCL13 and CXCL9 in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e36-e53.	2.4	29
34	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 53-62.	2.4	6
35	New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 206-208.	1.2	0
36	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	1.6	119

#	ARTICLE	IF	CITATIONS
37	Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943.		23
38	Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096236.	3.2	1
39	An overview of antibody–drug conjugates in oncological practice. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096299.	3.2	15
40	Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 1465-1477.	10.7	330
41	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
42	Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma. Oncologist, 2020, 25, e1209-e1220.	3.7	7
43	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 395, 1835-1844.	13.7	423
44	A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy. Medicine (United States), 2020, 99, e19439.	1.0	1
45	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. Cancer Genomics and Proteomics, 2020, 17, 181-193.	2.0	2
46	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	21.4	138
47	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. Cancer Immunology, Immunotherapy, 2020, 69, 1549-1564.	4.2	19
48	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. Journal of Clinical Oncology, 2020, 38, 10012-10012.	1.6	14
49	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget, 2020, 11, 1-14.	1.8	1
50	301–Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study. , 2020, , .		0
51	Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 4185-4190.	1.1	13
52	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 121, 144-153.	2.8	27
53	Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. Cancer Medicine, 2019, 8, 6585-6594.	2.8	31
54	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 119, 168-178.	2.8	61

#	ARTICLE	IF	CITATIONS
55	Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. , 2019, 7, 239.		81
56	A life-threatening drug-drug interaction between capecitabine and brivudine in a patient with metastatic breast cancer. <i>Journal of Chemotherapy</i> , 2019, 31, 424-427.	1.5	4
57	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	27.0	909
58	Opposite Prognostic Impact of Single PTEN-loss and <i>PIK3CA</i> Mutations in Early High-risk Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 195-206.	2.0	13
59	Adverse events 2.0”Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	2.8	19
60	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 765-772.	4.2	35
61	A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors. <i>Oncologist</i> , 2019, 24, e755-e764.	3.7	11
62	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019, 25, 1916-1927.	30.7	541
63	Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors. <i>Melanoma Research</i> , 2019, 29, 428-434.	1.2	0
64	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	7.1	295
65	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9584-9584.	1.6	6
66	Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature. <i>Journal of Immunotherapy</i> , 2018, 41, 164-167.	2.4	20
67	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. <i>Clinical Breast Cancer</i> , 2018, 18, 53-62.e3.	2.4	8
68	Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 648-651.	1.2	23
69	Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. <i>Cancer Medicine</i> , 2018, 7, 5066-5082.	2.8	12
70	Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center. <i>Melanoma Research</i> , 2018, 28, 348-358.	1.2	6
71	Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. <i>PLoS ONE</i> , 2018, 13, e0200302.	2.5	21
72	Abdominal Emergencies in Patients with Stage IV Melanoma: The Role of Surgery: A Single-centre Experience. <i>Anticancer Research</i> , 2018, 38, 3713-3718.	1.1	4

#	ARTICLE	IF	CITATIONS
73	Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 3840-3852.	8.2	79
74	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9502-9502.	1.6	52
75	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in <i>BRAF</i>-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9504-9504.	1.6	23
76	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18609-e18609.	1.6	0
77	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. <i>Journal of Translational Medicine</i> , 2017, 15, 30.	4.4	14
78	Mucosal melanoma of the head and neck. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 136-152.	4.4	125
79	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	2.8	160
80	Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. <i>Cancer Investigation</i> , 2017, 35, 443-455.	1.3	67
81	Acquired IFN γ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. <i>Nature Communications</i> , 2017, 8, 15440.	12.8	195
82	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. <i>Translational Oncology</i> , 2017, 10, 589-598.	3.7	17
83	Hypercalcemia of malignancy treated with cinacalcet. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2017, 2017, .	0.5	13
84	Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2017, 37, 2334.	1.1	10
85	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 2947-2957.	1.1	9
86	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 181-195.	2.0	30
87	The fate of BRCA1-related germline mutations in triple-negative breast tumors. <i>American Journal of Cancer Research</i> , 2017, 7, 98-114.	1.4	4
88	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. <i>Oncotarget</i> , 2016, 7, 32731-32753.	1.8	30
89	Toxicity management of immunotherapy for patients with metastatic melanoma. <i>Annals of Translational Medicine</i> , 2016, 4, 272-272.	1.7	92
90	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. <i>PLoS ONE</i> , 2016, 11, e0163138.	2.5	8

#	ARTICLE	IF	CITATIONS
91	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 307-321.	2.5	16
92	MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 136.	4.4	25
93	IFN- γ cancer immunotherapy: new kid on the block. <i>Immunotherapy</i> , 2016, 8, 877-888.	2.0	30
94	Prediction of Melanoma Risk in a Southern European Population Based on a Weighted Genetic Risk Score. <i>Journal of Investigative Dermatology</i> , 2016, 136, 690-695.	0.7	25
95	Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016, 16, 291-298.e3.	2.4	17
96	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. <i>PLoS ONE</i> , 2016, 11, e0164013.	2.5	4
97	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. <i>Oncotarget</i> , 2016, 7, 5074-5087.	1.8	54
98	Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 2365-78.	1.1	6
99	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. <i>Journal of Translational Medicine</i> , 2015, 13, 171.	4.4	15
100	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>PLoS ONE</i> , 2015, 10, e0140293.	2.5	29
101	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	13.7	1,175
102	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	2.8	269
103	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , The, 2015, 16, 15-17.	10.7	10
104	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	27.0	4,795
105	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
106	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 102-102.	1.6	3
107	Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin–vinblastine–temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG). <i>Anticancer Research</i> , 2015, 35, 1105-13.	1.1	8
108	Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. <i>Anticancer Research</i> , 2015, 35, 4023-36.	1.1	8

#	ARTICLE	IF	CITATIONS
109	Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17. PLoS ONE, 2014, 9, e103707.	2.5	3
110	Emergency Surgery for Metastatic Melanoma. International Journal of Surgical Oncology, 2014, 2014, 1-4.	0.6	5
111	Survivin beyond physiology: Orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Letters, 2014, 347, 175-182.	7.2	57
112	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New England Journal of Medicine, 2014, 371, 1877-1888.	27.0	1,572
113	alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. BMC Clinical Pathology, 2014, 14, 28.	1.8	13
114	A New Mathematical Model for the Interpretation of Translational Research Evaluating Six CTLA-4 Polymorphisms in High-Risk Melanoma Patients Receiving Adjuvant Interferon. PLoS ONE, 2014, 9, e86375.	2.5	3
115	Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes. PLoS ONE, 2014, 9, e91407.	2.5	15
116	Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. Anticancer Research, 2014, 34, 3083-92.	1.1	19
117	Immunotherapy for advanced melanoma: Fulfilling the promise. Cancer Treatment Reviews, 2013, 39, 879-885.	7.7	44
118	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Research and Treatment, 2012, 132, 609-619.	2.5	48
119	Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: A Phase II Trial of the Hellenic Cooperative Oncology Group. Clinical Breast Cancer, 2010, 10, 230-237.	2.4	17
120	Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer, 2010, 116, 4326-4333.	4.1	35
121	Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. Journal of Translational Medicine, 2010, 8, 108.	4.4	25
122	Reply to S.S. Agarwala et al. Journal of Clinical Oncology, 2009, 27, e84-e84.	1.6	0
123	Reply to P. Mohr et al. Journal of Clinical Oncology, 2009, 27, e71-e71.	1.6	0
124	Vinorelbine in Combination with Interleukin-2 as Second-Line Treatment in Patients with Metastatic Melanoma. A Phase II Study of the Hellenic Cooperative Oncology Group. Cancer Investigation, 2004, 22, 832-839.	1.3	10
125	The role of taxanes in the treatment of metastatic melanoma. Melanoma Research, 2004, 14, 415-420.	1.2	25
126	Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year—a Hellenic Cooperative Oncology Group study. Anticancer Research, 2004, 24, 1947-52.	1.1	16

#	ARTICLE	IF	CITATIONS
127	Lymphocyte Subpopulations and Interleukin Levels in High-Risk Melanoma Patients Treated With High-Dose Interferon A-2B. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 591-596.	1.3	4